AUROBINDO

January 30, 2020

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: USFDA classifies the inspection of Company's Unit-VII facility as OAI

Further to our intimations dated 7th & 11th October, 2019 with regard to the USFDA inspection of Unit VII, an oral solids formulation manufacturing facility of the Company, we inform you that the Company has received a letter from the USFDA classifying the inspection conducted at the aforesaid facility as Official Action Indicated (OAI).

The Company believes that this OAI classification will not have any material impact on the existing revenues or the supplies to our US business at this juncture. The Company will work closely with the regulator to comprehensively address the issues.

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B.Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. * HYD. *